TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females without compromised immune system~* Have a body mass Index of 18 to 32 kilograms per square meter (kg/m²)~Exclusion Criteria:~* Previously completed or withdrawn from an ixekizumab study or a study investigating interleukin-17 (IL-17) antagonists~* Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed~* Have known allergy or hypersensitivity to any biologic therapy~* Past vaccination allergy or Arthus-type hypersensitivity~* Received a tetanus toxoid-containing vaccine within the last 5 years~* Severe allergic reaction to Boostrix~* Allergic to latex~* Have been immunized with pneumococcal vaccine~* Known hypogammaglobulinemia~* History of Guillain-Barre Syndrome~* Active infectious disease~* Had a live vaccination within 1 year prior to screening, or intend to have a live vaccination during the course of the study~* Evidence of a significant uncontrolled neuropsychiatric disorder -~* Have a score of 3 on Item 12 of the Quick Inventory of Depressive Symptomatology-Self Report (16 Items) at screening~* Evidence of Human Immunodeficiency Virus infection, Hepatitis C, B~* Had symptomatic herpes zoster within 3 months of screening~* Women who are lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ixekizumab + Boostrix® + Pneumovax®23 (Type: EXPERIMENTAL): Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2.
- Boostrix® + Pneumovax®23 (Type: OTHER): Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received a kidney transplant ≥ 9 weeks at time of Screening and ≤ 24 months before first dose~* May be the first kidney transplant or a repeat kidney transplant.~* Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² (chromic kidney disease stage 3 or better) at Screening.~* Men or women ≥ 18 years at the start of Screening (ie, time of informed consent).~* Corrected total serum calcium \> 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values in Screening period.~* iPTH \> 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen 1 or Screen 2).~Exclusion Criteria:~* Received cinacalcet therapy post-transplant for more than 14 days cumulatively post-transplant. If cinacalcet therapy was received for a total of 14 days or less post-transplant, there must be a 4-week washout before subject is eligible for screening (Note: This does not exclude pre-transplant use of cinacalcet).~* Anticipated parathyroidectomy within 6 to12 months after Randomization.~* Ongoing therapy with bisphosphonates or use within 6 months prior to Screening.~* Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to Screening.~* Ongoing use of calcium supplements or use within 30 days prior to Screening.~* Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to Screening.~* Ongoing use of a thiazide diuretic.~* Subjects with a history of seizures who had a seizure within the 3 months prior to Randomization, which required adjustments to the seizure medication.~* Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: EXPERIMENTAL): Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled for elective Cardiac or Thoracic Surgery.~* Age \> 18 years of age.~Exclusion Criteria:~* Patients with a clinical suspicion or a documented history of DVT/PE~* Patients who may require anticoagulation during the post-op period. (i.e. Patients with a history of A-fib, scheduled for a MAZE procedure or placement of a mechanical valve, or those on Coumadin/IV heparin preoperatively)~* Patients who have a history of HIT or if there is a suspicion of the patient having HIT pre-operatively.~* Documented allergy to heparin, desirudin, or lepirudin~* Patients with a history of coagulation disorder~* Platelet count\< 100 X109 /dl~* Active bleeding~* Serum Creatinine ≥ 1.5 mg/dl or CrCl ≤ 30 ml/min~* Patients with a baseline coagulopathy (INR \> 1.5 or aPTT \> 45 sec)~* Patients with liver disease~* Pregnancy~* Patients who require ventricular assist devices before or after surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heparin (Type: ACTIVE_COMPARATOR): Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
- Desirudin (Iprivask™) (Type: EXPERIMENTAL): Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV) criteria~* total score on the PANSS at study entry of \>=50~* before trial entry, results of clinical hematology, biochemistry, and urinalysis tests performed at screening visit are within normal ranges~* women of child-bearing age must use adequate birth control methods, have a negative pregnancy test before the start of risperidone treatment, and not be breast feeding~* patients' schizophrenia symptoms are stable for the last 4 weeks of the run-in period.~Exclusion Criteria:~* Patients with a DSM-IV Axis I diagnosis other than schizophrenia~* documented disease of the central nervous system that can interfere with the trial assessments, for example stroke, tumor, Parkinson's Disease, Alzheimer's Disease~* moderate or severe symptoms at screening of tardive dyskinesia, a condition of uncontrollable movements of the tongue, lips, face, trunk, hands and feet that is seen in patients receiving long-term medication with certain types of antipsychotic drugs~* history of neuroleptic malignant syndrome, a rare condition in patients receiving antipsychotic medication in which patients may develop fever, sweating, unstable blood pressure, rigid muscles, and other symptoms, including changes in their normal mental state~* acute, unstable or other significant and untreated medical conditions, such as infections, unstable diabetes, or unstable hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed ileal, ileo-colonic, or colonic CD at least 6 months prior to screening.~* Men or women age 18 - 65 years at the time of screening.~* Moderate-sever active Crohn's Disease (CD), defined by a Crohn's Disease Activity Index (CDAI) score higher or equal 220 and lower or equal 450 at Day 1.~* No known history of active tuberculosis (TB).~* Received at least one anti-TNFα agent for the treatment of CD and did not initially respond.~Exclusion Criteria:~* Pregnant or breastfeeding women.~* Presence of ileostomy and/or colostomy.~* Short bowel syndrome.~* Bowel perforation or obstruction.~* History of cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MEDI2070 iv infusion
- 2 (Type: PLACEBO_COMPARATOR): placebo iv infusion
- open-label (Type: EXPERIMENTAL): MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical DHEA Against Vaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women (non hysterectomized or hysterectomized)~* Women between 40 and 75 years of age~* Willing to participate in the study and sign an informed consent~* Women having a low maturation index (no greater part of guidance than 5% of superficial cells on vaginal smear)~* Women having a vaginal pH above 5~* Women who have self-identified at least one moderate to severe symptoms of vulvovaginal atrophy~Exclusion Criteria:~* Undiagnosed abnormal genital bleeding~* Hypertension equal to or above 160/95 mm Hg or not controlled by standard therapy~* The administration of any investigational drug within 30 days of screening visit~* Endometrial hyperplasia at biopsy performed at screening or endometrial cancer~* Use of estrogens/progestins products (vaginal, oral, pellet, transdermal, etc) in the 4 weeks to 6 months (depending on the product used) prior study entry

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 0.25% DHEA (Type: EXPERIMENTAL): None
- 0.5% DHEA (Type: EXPERIMENTAL): None
- 1.0% DHEA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Male or female volunteer~2. Age 18-65~3. Sea-level dwelling~4. Non pregnant~5. Have not been to high altitude in the past week~6. Can arrange for their own transportation to WMRS by friday evening the weekend of their study enrollment and are available the duration of the weekend of their study enrollment~Exclusion Criteria:~1. Age \<18 or \>65~2. Live at altitude \> Sea Level +/- 1000'~3. Pregnant~4. Taking NSAIDs, Acetazolamide, or Corticosteroids~5. Allergic to NSAIDs or Aspirin, or have had adverse reaction to them in the past~6. Traveled or planning to travel to high altitude in the week prior to their enrollment.~7. Medical history of Brain Tumor, increased intercranial pressure, pseudotumor cerebri, ventricular shunts, loss of an eye, Asthma, HACE or HAPE.~8. Cannot arrange for their own transportation to WMRS or are unavailable for the duration of the weekend of their study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ibuprofen (Type: ACTIVE_COMPARATOR): 600mg ibu TID
- placebo (Type: PLACEBO_COMPARATOR): visually identical

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-65 years of age;~* previously untreated indolent nonfollicular non-Hodgkin's lymphoma;~* active disease;~* \>=3 involved sites.~Exclusion Criteria:~* typical chronic lymphocytic leukemia;~* other malignancies within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix;~* systemic corticosteroid use for \>1 month;~* significant cardiovascular disease;~* central nervous system involvement;~* hepatitis B or C virus infection, or HIV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged between 18-80 year-old~2. The onset of stroke must be at least 6 months previously~3. Spasticity measured as Modified Asthow Scale more(MAS) than 1+~4. Signed informed consent form~Exclusion Criteria:~1. Patients with marked contractures in the elbow and wrist (MAS\>4)~2. Resistant hypertension, coagulation disorders, malignant tumors, pregnancy, pacemakers, cognitive disorders~3. Prior or planned treatment with phenol or alcohol nerve blocks, intrathecal baclofen, or BoNT-A injection within the six months preceding the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- shock wave (Type: EXPERIMENTAL): The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
- Botulinum toxin A (Type: EXPERIMENTAL): We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults \>/= 60 to \</=64 years of age (from the 60th birthday up to, but not including, the 65th birthday) at enrollment.~2. Healthy adults, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy or requiring hospitalization within 3 months before receipt of investigational product, as determined by medical history, physical examination, laboratory screening, and clinical judgment of the investigator.~3. Female subjects who are not of childbearing potential.~Exclusion Criteria:~1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.~2. History of microbiologically proven invasive disease caused by S pneumoniae.~3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Multivalent (Type: EXPERIMENTAL): Pneumococcal conjugate vaccine
- Control (Type: ACTIVE_COMPARATOR): Prevnar 13 and PPSV23

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of the Use of Intraperitoneal Local Anaesthetic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All they patients undergoing laparoscopic cholecystectomy will be included.~Exclusion Criteria:~* Patients with local anaesthetic allergy, patients on chronic opiate medication or those with neurological diseases that make pain evaluation unreliable will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: SHAM_COMPARATOR): No intraperitoneal therapeutics (No nebulised Bupivacaine)
- IP Aerosolized Normal Saline (Type: PLACEBO_COMPARATOR): Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
- Nebulised Bupivacaine intraperitoneally (Type: EXPERIMENTAL): Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
- Injected Bupivacaine intraperitoneally (Type: ACTIVE_COMPARATOR): Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exenatide in Extreme Pediatric Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index \> or = 1.2 times the 95th percentile (based on gender and age) or Body mass index \> or = 35 kg/m2~* 12-19 years old~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Previous (within 3-months) or current use of weight loss medication (patients may undergo washout)~* Previous bariatric surgery~* Recent initiation (within 1-month) of anti-hypertensive or lipid medication~* Previous (within 1-month) or current use of medication to treat insulin resistance or hyperglycemia (patients may undergo washout)~* Major psychiatric disorder~* Pregnant or planning to become pregnant~* Tobacco use~* Liver/renal dysfunction~* History of pancreatitis~* Obesity associated with genetic disorder~* Hyperthyroidism or uncontrolled hypothyroidism~* Uncontrolled hypertriglyceridemia (=300 mg/dL)~* Current eating disorder~* Previous (within 3-months) or current use of drugs associated with weight gain (e.g. steroids/anti-psychotics)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide, then Open-Label Exenatide (Type: EXPERIMENTAL): Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
- Placebo, then Open Label Exenatide (Type: PLACEBO_COMPARATOR): Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete